Editas Medicine, Inc. (EDIT) 2024 Cantor Global Healthcare Conference (Transcript)

Editas Medicine, Inc. ( NASDAQ: EDIT ) 2024 Cantor Global Healthcare Conference September 17, 2024 1:20 PM ET

Company Participants

Gilmore O’Neill - CEO

Conference Call Participants

Eric Schmidt - Cantor Fitzgerald

Eric Schmidt

Good afternoon, everyone. My name is Eric Schmidt, and I'm one of the, biotechnology analyst at Cantor Fitzgerald. So welcome to, the afternoon of day one of our Annual Healthcare Conference. With me today for this session is, Editas. We're delighted to have with us the company's Chief Executive Officer, Gilmore O’Neill. Gilmore, welcome.

Gilmore O’Neill

Thank you very much, Eric. It's great to be here.

Question-and-Answer Session

Q - Eric Schmidt

So we're going, have a nice little fireside chat about, hopefully, all things that that matter to this company as they try to bring innovative new medicines to patients in need. Feel free to make this interactive. We've got a relatively modest sized group here, so we can we can engage with you all. But maybe, Gilmore, just start with, the high level view for those little less familiar with the company. Where are you these days? What are your priorities?

Gilmore O’Neill

Thanks very much, Eric. Actually, one thing is you post -- you used the word innovative. And I want to say that we are interested in innovation, but not for the sake of being innovative. We're interested in innovation for the sake of having a high impact on patient outcomes, and that's a very important part as we drive towards being a leader in the long-term of in-vivo curative therapeutics.

So where the company is today is, we're executing against the three pillars of our strategy. One, to drive Reni-cel to approval, very importantly to build a in-vivo discovery pipeline, which is differentiated and focusing on developing therapeutics that'd be first-in-class or best-in-class, And then the third pillar is to